65: Thyroid Cancer Does Not Respond to RAI⎢Treatment Options

In this episode, topics include: * Drug therapy for patients that fail standard therapy; including surgery and RAI * Not all patients have same behavior for their cancer * Some cancers are aggressive * Not many thyroid cancer patients are affected by this; maybe a few thousand in the U.S., but not tens of thousands * What is the treatment protocol for therapy? * Lenvatinib or Sorafenib is the treatment for refectory thyroid cancer * Lenvatinib tends to be more effective * Sorafenib is tolerated by the patient better * Other options to consider include, molecular profiling or some thyroid cancers carry mutation that is targetable, or BRAF * BRAF inhibitors used with thyroid cancer patients * Molecular profiling * DNA sequencing

Continue Reading
Close Menu

Subscribe to Doctor Thyroid with Philip James Newsletter

No spam. Your information is safe.
It will not be shared with any third party.
You can unsubscribe at any time.